Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-10-23
2007-10-23
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S256000, C546S193000, C544S333000
Reexamination Certificate
active
10696464
ABSTRACT:
This invention provides 4-amino-1-(pyridylmethyl)piperidine and related compounds and pharmaceutically acceptable salts thereof which are useful as muscarinic receptor antagonists. This invention also provides pharmaceutical compositions containing such compounds; processes and intermediates useful for preparing such compounds; and methods for treating disease conditions mediated by muscarinic receptors, such as overactive bladder, irritable bowel syndrome and chronic obstructive pulmonary disease, using such compounds.
REFERENCES:
patent: 3192206 (1965-06-01), Lunsford et al.
patent: 3192210 (1965-06-01), Lunsford et al.
patent: 3192221 (1965-06-01), Lunsford et al.
patent: 3984557 (1976-10-01), Welstead, Jr.
patent: 4002766 (1977-01-01), Welstead, Jr.
patent: 4594343 (1986-06-01), Shanklin, Jr. et al.
patent: 4810713 (1989-03-01), Yanni et al.
patent: 4950674 (1990-08-01), Yanni et al.
patent: 5026858 (1991-06-01), Vega-Noverola et al.
patent: 5028616 (1991-07-01), Desai et al.
patent: 5070087 (1991-12-01), Teng et al.
patent: 5096890 (1992-03-01), Cross et al.
patent: 5233053 (1993-08-01), Cross et al.
patent: 5281601 (1994-01-01), Cross et al.
patent: 5340831 (1994-08-01), Cross et al.
patent: 5344835 (1994-09-01), Alker et al.
patent: 5486527 (1996-01-01), Alker et al.
patent: 5607950 (1997-03-01), Alker et al.
patent: 5750540 (1998-05-01), Tsuchiya et al.
patent: 5932594 (1999-08-01), Cross et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6319920 (2001-11-01), Caroon et al.
patent: 6635764 (2003-10-01), Mammen et al.
patent: 6693202 (2004-02-01), Aggen et al.
patent: 2002/0049195 (2002-04-01), Mammen et al.
patent: 2003/0055080 (2003-03-01), Forner et al.
patent: 2004/0029919 (2004-02-01), Mammen et al.
patent: 2004/0054187 (2004-03-01), Mammen et al.
patent: 2004/0110229 (2004-06-01), Aggen et al.
patent: 2004/0116706 (2004-06-01), Mammen et al.
patent: 2005/0026954 (2005-02-01), Mammen et al.
patent: 628 885 (1982-03-01), None
patent: 0 178 946 (1986-04-01), None
patent: 0 178 947 (1986-04-01), None
patent: 0 235 463 (1987-09-01), None
patent: 0 388 054 (1990-09-01), None
patent: 0 863 141 (1998-09-01), None
patent: 0 930 298 (1999-07-01), None
patent: 0 999 205 (2000-05-01), None
patent: 1 020 449 (2000-07-01), None
patent: 1 507 462 (1978-04-01), None
patent: 1 575 310 (1980-09-01), None
patent: 1 593 851 (1981-07-01), None
patent: WO91/09013 (1991-06-01), None
patent: WO99/43657 (1999-09-01), None
patent: WO99/64043 (1999-12-01), None
patent: WO 01/04118 (2001-01-01), None
patent: WO 02/051841 (2002-07-01), None
patent: WO 02/053564 (2002-07-01), None
patent: WO 03/048124 (2003-06-01), None
Bohme et al., 2002, J. Med. Chem., 45, 4800.
Bohme et al., 2002, J. Med. Chem., 45, 3094-3102.
Walsh et al., J. Med. Chem., 1989, 32, pp. 105-118.
Boselli et al., Journal of Autonomic Pharmacology, 2001, 21, p. 219-229.
Beringue, et al., 1997, CA 126: 324757, Abstract.
Tomlinson et al., 1997, CA 127: 174580, Abstract.
Berge et al. “Pharmaceutical salts” J. Pharm. sciences, vl. 66, p. 1-2 (1977).
Pratesi et al. “Affinity and intrinsic . . . ” CA 70:37081 (1969).
CA 60:74793 (1964), see marked entry.
Laeckmann et al. “Synthesis and biological . . . ” Bioorg. med. Chem. v. 10 (2002) p. 1793-1804.
Wermuth “The practice of medicinal chemistry” (1996) p. 203-213.
Broadley et al., “Muscarinic Receptor Agonists and Antagonists”, Molecules 2001, 6, pp. 142-193 (2001).
Eglen et al., “Muscarinic Receptor Subtypes: Pharmacology and Therapeutic Potential”, DN&P, 10(8), pp. 462-469 (1997).
Eglen et al., “Selective modulation of muscarinic receptor subtypes: therapeutic potential”, Emerging Drugs:The Prospect for Improved Medicines/Annual Executive Briefing 1998; pp. 67-79 (1998).
Graul et al., “Darifenacin”, Drugs of the Future 1996, 21 (11); pp. 1105-1108 (1996).
Moragues et al., “Dopaminergic Activity in a Series of N-Substituted 2-Aminopyrimidines”, II Farmaco -Ed. Sc. -vol. 35—Fasc. 11; pp. 951-964 (1980).
Shum et al., “The Design and Synthesis of Purine Inhibitors of CDK2.III”, Nucleosides, Nucleotides & Nucleic Acids, 20(4-7), pp. 1067-1078 (2001).
Zlotos et al., “Muscarinic receptor agonists and antagonists”, Exp. Opin. on Ther. Patents, 9(8), pp. 1029-1053 (1999).
Chen Yan
Dunham Sarah
Hughes Adam
Husfeld Craig
Ji Yu-Hua
Chang Celia
Hagenah Jeffrey A.
Theravance Inc.
LandOfFree
Substituted 4-amino-1-(pyridylmethyl)piperidine and related... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 4-amino-1-(pyridylmethyl)piperidine and related..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4-amino-1-(pyridylmethyl)piperidine and related... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3880433